AIM ImmunoTech (AIM) investor relations material

Strategic focus and rationale

• Ampligen's development is now prioritized for pancreatic cancer due to its high lethality, rapid progression, and significant unmet medical need, with over 450,000 deaths worldwide annually.

• Ampligen has shown positive data in multiple solid tumors, but pancreatic cancer was chosen for its market size, lack of effective therapies, and moral imperative.

• Orphan drug designations in the US and EU provide market exclusivity post-approval, enhancing the business case.

• Intellectual property and collaborations with industry and government support the program's advancement.

• The business model aims for acquisition or licensing by a major pharmaceutical company after Phase 3 readiness.

Clinical progress and data

• Over 75 subjects have been treated in pancreatic cancer studies, with strong safety and efficacy data.

• Ampligen extends median overall survival by more than eight months compared to historical controls, with improved quality of life.

• The drug is well-tolerated and restores immune function, countering the immunosuppression caused by chemotherapy.

• Biomarkers such as CA19-9 and neutrophil/lymphocyte ratios help identify strong responders and inform trial design.

• Phase 2 is nearing completion, with primary and secondary endpoint data expected within the next year.

Mechanism of action and differentiation

• Ampligen activates Toll-like 3 receptors in epithelial tumors, converting immune-silent (cold) tumors into immune-active (hot) tumors.

• Functions as both monotherapy and in combination with checkpoint inhibitors, enhancing their effectiveness.

• Demonstrated synergy with Keytruda in ovarian and triple-negative breast cancer trials.

• The immune system boost from Ampligen reduces infections and comorbidities in immunosuppressed patients.

• The approach offers a broad platform potential for other solid tumors beyond pancreatic cancer.